reports
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History ...
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025 RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene Patients Experience High Burden of Arrhythmias and Severe Disease Progression Despite Standard-of-Care Treatments Large Majority of PKP2-associated ARVC Patients Appear Eligible for TN-401 Gene Therapy Based on Low Rates of Preexisting Immunity to AAV9 Antib...
- Dave Nicoski
- Ross LaDuke
BKD BROOKDALE SENIOR LIVING INC.
STRL STERLING CONSTRUCTION COMPANY INC.
SLP SIMULATIONS PLUS
MKTX MARKETAXESS HOLDINGS INC.
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
HII HUMANA INC.
HCA HUNTINGTON INGALLS INDUSTRIES INC.
GD HCA HEALTHCARE INC
DLTR GENERAL DYNAMICS CORPORATION
DG DOLLAR TREE INC.
CVGW DOLLAR GENERAL CORPORATION
CNC CALAVO GROWERS INC.
CL CENTENE CORPORATION
CACI COLGATE-PALMOLIVE COMPANY
FDP CACI INTERNATIONAL INC CLASS A
SJW FRESH DEL MONTE PRODUCE INC.
LKO SJW GROUP
FIZZ LAKES OIL N.L.
CELH NATIONAL BEVERAGE CORP.
PAGS CELSIUS HOLDINGS INC.
STNE PAGSEGURO DIGITAL LTD
LHX STONECO
CERT L3HARRIS TECHNOLOGIES INC
MASS CERTARA
CTGO 908 DEVICES
NTST CONTANGO ORE INC.
YOU NETSTREIT CORP
HUM CLEAR SECURE INC
HAMILTON U.S. MID-CAP FINANCIALS ETF
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of NextEra Energy, Inc., Florida Power & Light Company, NextEra Energy Capital Holdings, Inc. and other ratings that are associated with these issuers. The review was conducted through a rating committee held on 26 March 2025 ...
Tenaya Therapeutics Announces Late Breaker Presentation of New Data fr...
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I Two of Three Patients Experienced Improvements in One or More Measures of Hypertrophy Expects to Complete Enrollment of Cohort 2 in 1H25 and to Report Initial Data in 2H25 ...
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 En...
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models Robust Evidence of Disease Reversal in Severe Knock Out Mice Model Supports Tenaya’s Clinical Development Plan to Evaluate TN-201 as a Potential Treatment for Patients with MYBPC3-associated Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that addres...
Tenaya Therapeutics Announces Late Breaker and New Data Presentations ...
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that new clinical and disease burden data pert...
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financia...
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data Accepted for Late-Breaker Presentation at the American College of Cardiology Meeting Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25 Recent $48.9 Million Financing Extends Cash Runway into mid-2026 SOUTH SAN FR...
- Jonathan Moreland
PEB PEBBLEBROOK HOTEL TRUST
PBF PBF ENERGY INC. CLASS A
MTDR MATADOR RESOURCES COMPANY
MPC MARATHON PETROLEUM CORPORATION
LTRX LANTRONIX INC.
FRPT FRESHPET INC
EIX EDISON INTERNATIONAL
DRTTF DIRTT ENVIRONMENTAL SOLUTIONS
CMCO COLUMBUS MCKINNON CORPORATION
FLWS 1-800-FLOWERS.COM CL A
JELD JELD-WEN HOLDING INC.
FRAF FRANKLIN FINANCIAL SERVICES CO.
ELAN ELANCO ANIMAL HEALTH INC.
ABCL ABCELLERA BIOLOGICS
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
JANX JANUX THERAPEUTICS INC
TNYA TENAYA THERAPEUTICS INC
IE IVANHOE ELECTRIC INC
ECAT BLACKROCK ESG CAP ALLOCATION TR
ELTX ANGION BIOMEDICA CORP
CVI CVR ENERGY
GAM INC.
GENERAL DE ALQUILER DE MAQUINARIA
Tenaya Therapeutics Announces Pricing of Public Offering
Tenaya Therapeutics Announces Pricing of Public Offering SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 75,000,000 total units for gross proceeds of approximately $52.5 million prior to deducting underwriting discounts and commissions and offering expenses. Tenaya intends to use the net procee...
Tenaya Therapeutics Announces Proposed Public Offering
Tenaya Therapeutics Announces Proposed Public Offering SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and Series A warrants and Series B warrants, each to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pr...
Tenaya Therapeutics to Participate in Upcoming March Investor Conferen...
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in TD Cowen’s 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. Details are as follows: TD Cowen 45th Annual Heal...
Tenaya Therapeutics Receives $8 Million Clinical Grant from California...
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine Funding will Support Ongoing RIDGE™-1 Clinical Trial of TN-401 Gene Therapy for the Potential Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Initial Data from RIDGE-1 Phase 1b Clinical Trial Expected in 2H25 SOUTH SAN FRANCISCO, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies tha...
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipate...
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Additional Cohort 1 Data to be Reported in 1H25 Building on Promising Initial Data Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25 SOUTH SAN FRANCISCO, Calif., Jan. 13, ...
- Jonathan Moreland
OXY OCCIDENTAL PETROLEUM CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
VRSN VERISIGN INC.
TTSH TILE SHOP HOLDINGS INC.
RMAX RE/MAX HOLDINGS INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
PBF PBF ENERGY INC. CLASS A
NMFC NEW MOUNTAIN FINANCE CORPORATION
MTDR MATADOR RESOURCES COMPANY
MMS MAXIMUS INC.
DLY LYONDELLBASELL INDUSTRIES NV
KVHI KVH INDUSTRIES INC.
HRZN HORIZON TECHNOLOGY FINANCE CORP.
GLP GLOBAL PARTNERS LP
FPI FARMLAND PARTNERS REIT
FISI FINANCIAL INSTITUTIONS INC.
FFIC FLUSHING FINANCIAL CORP.
CNC CENTENE CORPORATION
CULP CULP INC.
FI FRANK'S INTERNATIONAL NV
NSC NORFOLK SOUTHERN CORPORATION
PETS PETMED EXPRESS INC.
PLSE PULSE BIOSCIENCES
SENS SENSEONICS HOLDINGS
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
TDW TIDEWATER INC
DOW DOW INC.
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
BCYC BICYCLE THERAPEUTICS
OXLC OXFORD LANE CAPITAL CORP.
PHAT PHATHOM PHARMACEUTICALS
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
REYN REYNOLDS CONSUMER PRODUCTS INC.
PRLD PRELUDE THERAPEUTICS
DLHC DALEIGH HOLDINGS CORP
MASS 908 DEVICES
CTGO CONTANGO ORE INC.
UAN CVR PARTNERS LP
PFX PHENIXFIN CORP
RMBL RUMBLEON INC
XLO XILIO THERAPEUTICS INC
NVCT NUVECTIS PHARMA INC
BIGZ BLACKROCK INNOVATION AND GROWTH TST
BHRB BURKE & HERBERT BANK & TR/VA
ECBK ECB BANCORP INC.
DINO HF SINCLAIR CORP
TKO TKO GROUP HOLDINGS
GAM INC.
MIO GENERAL DE ALQUILER DE MAQUINARIA
SUNS PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
MDRR SUNRISE REALTY TRUST
SIRI MEDALIST DIVERSIFIED REIT INC.
EVM SIRIUS XM HLDGS INC NEW
TXO EATON VANCE INSD CALIF MUN BD FD
MORNINGSTAR PARTNERS
L.P.
- Jonathan Moreland
HPP HUDSON PACIFIC PROPERTIES INC.
VRSN VERISIGN INC.
RMAX RE/MAX HOLDINGS INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
CNC CENTENE CORPORATION
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
REYN REYNOLDS CONSUMER PRODUCTS INC.
DLHC DALEIGH HOLDINGS CORP
MASS 908 DEVICES
XLO XILIO THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
DINO HF SINCLAIR CORP
MIO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
SIRI SIRIUS XM HLDGS INC NEW
EVM EATON VANCE INSD CALIF MUN BD FD
TXO MORNINGSTAR PARTNERS
L.P.
Centene Corp: 1 director
A director at Centene Corp bought 17,000 shares at 59.750USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- Jonathan Moreland
PBF PBF ENERGY INC. CLASS A
NMFC NEW MOUNTAIN FINANCE CORPORATION
HRZN HORIZON TECHNOLOGY FINANCE CORP.
CNC CENTENE CORPORATION
FI FRANK'S INTERNATIONAL NV
PMD PSYCHEMEDICS CORP.
EB EVENTBRITE
DOW DOW INC.
BCYC BICYCLE THERAPEUTICS
OXLC OXFORD LANE CAPITAL CORP.
UAN CVR PARTNERS LP
BIGZ BLACKROCK INNOVATION AND GROWTH TST
SES SES AI CORPORATION
GAM GENERAL DE ALQUILER DE MAQUINARIA
MDRR MEDALIST DIVERSIFIED REIT INC.
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase ...
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting in Increasing RNA Expression and an Increase in Protein Levels Observed at One Year Circulating Biomarkers and Other Clinical Measures Mostly Remained Stable or Improved from Baseline Tenaya Management to Host a Webcast Conference Call Today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 17,...
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 ...
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Ph...
- Jonathan Moreland
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MCHX MARCHEX INC. CL B
LTRX LANTRONIX INC.
HSII HEIDRICK & STRUGGLES INTERNATIONAL INC.
HASI
I3N HANNON ARMSTRONG SUSTAINABLE INFRASTRUCTURE CAPITAL INC.
EXAS CHART INDUSTRIES INC.
EL EXACT SCIENCES CORPORATION
CROX ESTEE LAUDER COMPANIES INC. CLASS A
CNC CROCS INC.
BRKR CENTENE CORPORATION
APPS BRUKER CORPORATION
AVNW DIGITAL TURBINE
AIN AVIAT NETWORKS
CMCO ALBANY INTERNATIONAL CORP. CLASS A
ENPH COLUMBUS MCKINNON CORPORATION
HTLD ENPHASE ENERGY INC.
SACH HEARTLAND EXPRESS INC.
DMLP SACHEM CAPITAL
HLNE DORCHESTER MINERALS L.P.
ANGI HAMILTON LANE INCORPORATED CLASS A
MBIN ANGI INC. CLASS A
LILA MERCHANTS BANCORP
FF LIBERTY LATIN AMERICA A
MEC FIRST MINING GOLD
NOVA MAYVILLE ENGINEERING
GRWG SUNNOVA ENERGY INTERNATIONAL
PCB GROWGENERATION
CLDX PACIFIC CITY FINANCIAL CORP
FBRX CELLDEX THERAPEUTICS INC.
TFC FORTE BIOSCIENCES INC
ONEW TRUIST FINANCIAL CORP
ARRY ONEWATER MARINE
SSSS ARRAY TECHNOLOGIES
ABCL SUTTER ROCK CAPITAL CORP.
CSU ABCELLERA BIOLOGICS
IMNM CAPITAL SENIOR LIVING
GRNT IMMUNOME
PFBX GRANIT SKOPKE
TRIN PEOPLES FINANCIAL CORP. (MISSISSIPPI)
ZETA TRINITY CAPITAL INC
RWAY ZETA GLOBAL HLDGS CORP
ANTX RUNWAY GROWTH FINANCE CORP
NXGL AN2 THERAPEUTICS INC
CALC NEXGEL INC
DBD CALCIMEDICA INC.
CATX DIEBOLD NIXDORF INCORPORATED
MDRR PERSPECTIVE THERAPEUTICS
PDYN INC.
DC MEDALIST DIVERSIFIED REIT INC.
AGFY SARCOS TECHNOLOGY AND ROBOTICS CORP
ETS DAKOTA GOLD CORP.
AGRIFY CORPORATION
ENTERASYS NETWORKS INC /DE/
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.